NCT02234544 - Effect of an Inhibitor of Cholesterol Absorption on Vitamin D Levels | Biotech Hunter

Enrollment

52

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions

Vitamin D Deficiency

Interventions

DRUG

Ezetimibe

The groups will be randomized to ezetimibe 10 mg for 5 days or placebo. On the fifth day, they should came after an overnight fast for blood tests collection \[25(OH)D, PTH, calcium, albumin\]. Next, all participants will receive orally a cholecalciferol 50,000 IU capsule and a snack containing 15g of fat. Participants will return 14 days after that for a second blood test.

DRUG

Cholecalciferol

All participants will receive orally a cholecalciferol 50,000 IU capsule and a snack containing 15g of fat. Participants will return 14 days after that for a second blood test.

OTHER

Placebo

The groups will be randomized to ezetimibe 10 mg for 5 days or placebo. On the fifth day, they should came after an overnight fast for blood tests collection \[25(OH)D, PTH, calcium, albumin\]. Next, all participants will receive orally a cholecalciferol 50,000 IU capsule and a snack containing 15g of fat. Participants will return 14 days after that for a second blood test.

Trial Locations (1)

90035-903

Hospital de Clínicas de Porto Alegre, Porto Alegre